SAN DIEGO—(BUSINESS WIRE)—Jan. 5, 2016—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company
focused on the development and commercialization of innovative medicines
to address unmet medical needs in central nervous system disorders,
today announced that it intends to offer and sell, subject to market and
other conditions, $300,000,000 of shares of its common stock in an
underwritten public offering. There can be no assurance as to whether or
when the offering may be completed, or as to the actual size or terms of
the offering.
BofA Merrill Lynch and J.P. Morgan Securities LLC are acting as the
joint book-running managers for the offering. ACADIA intends to grant
the underwriters a 30-day option to purchase an additional $45,000,000
of shares of its common stock.
The shares of common stock described above are being offered by ACADIA
pursuant to a shelf registration statement filed by ACADIA with the
Securities and Exchange Commission (SEC) that became automatically
effective on March 3, 2014. A preliminary prospectus supplement related
to the offering will be filed with the SEC and will be available on the
SEC’s website located at http://www.sec.gov.
Copies of the preliminary prospectus supplement and the accompanying
prospectus related to this offering, when available, may be obtained
from BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, Email: [email protected],
or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at
866-803-9204.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development and
commercialization of innovative medicines to address unmet medical needs
in central nervous system disorders. ACADIA has a pipeline of product
candidates led by NUPLAZID™ (pimavanserin), for which we have submitted
a New Drug Application (NDA) in Parkinson’s disease psychosis to the FDA
and which has the potential to be the first drug approved in the United
States for this condition. The FDA has classified the NUPLAZID NDA as
having Priority Review status. Pimavanserin is also in Phase II
development for Alzheimer’s disease psychosis and has successfully
completed a Phase II trial in schizophrenia. ACADIA also has
clinical-stage programs for glaucoma and, in collaboration with
Allergan, Inc., for chronic pain.
Forward-Looking Statements
Statements in this press release that are not strictly historical in
nature are forward-looking statements. These statements include, but are
not limited to, statements related to the proposed offering of common
stock by ACADIA and the potential of NUPLAZID to be the first drug
approved in the United States for Parkinson’s disease psychosis. These
statements are only predictions based on current information and
expectations and involve a number of risks and uncertainties. Actual
events or results may differ materially from those projected in any of
such statements due to various factors, including market risks and
uncertainties and the satisfaction of customary closing conditions for
an offering of securities and the risks and uncertainties inherent in
drug discovery, development, approval and commercialization. For a
discussion of these and other factors, please refer to ACADIA’s annual
report on Form 10-K for the year ended December 31, 2014 as well as
ACADIA’s subsequent filings with the Securities and Exchange Commission.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. This caution is made
under the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are qualified in
their entirety by this cautionary statement and ACADIA undertakes no
obligation to revise or update this press release to reflect events or
circumstances after the date hereof, except as required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160105006733/en/
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Lisa Barthelemy, Director of
Investor Relations
(858) 558-2871